Background: Although community-acquired Staphylococcus aureus pneumonia with highly virulent Panton-Valentine leukocidin (PVL)-positive strains, a severe disease with significant lethality, is rare, especially in adult and adolescent patients, recent reports highlight that these infections are on the rise. Objectives: To describe the demographic and clinical features of reported cases of life-threatening community-acquired S. aureus pneumonia with usually PVL-positive strains in adult and adolescent patients, to evaluate the variables related to death, and to select a more appropriate antimicrobial treatment for this potentially deadly disease. Methods: We summarized all of the 92 reported cases and our case. The effect of 5 variables on mortality was measured using logistic regression. Results:S. aureus community-acquired pneumonia (CAP) with usually PVL-positive strains is a severe disease with significant lethality, i.e. 42.9%; a short duration of the time from the onset of symptoms to death, i.e. 5.5 ± 10.1 days, and prolonged hospital admissions, i.e. 33.2 ± 29.5 days. Seventy-three cases have been tested for the gene for PVL, and 71 strains have been found to carry the PVL gene. Logistic regression analysis showed that leucopenia (p = 0.002), influenza-like symptoms or laboratory-confirmed influenza (p = 0.011), and hemoptysis (p = 0.024) were the factors associated with death. Antibiotic therapies inhibiting toxin production were associated with an improved outcome in these cases (p = 0.007). Conclusions: Physicians should pay special attention to those patients who acquired severe CAP during influenza season and have flu-like symptoms, hemoptysis, and leucopenia, and they should consider S. aureus more frequently among the possible pathogens of severe CAP. Empiric therapy for severe CAP with this distinct clinical picture should include coverage for S. aureus. Targeted treatment with antimicrobials inhibiting toxin production appears to be a more appropriate selection.

Keywords:
Staphylococcus aureus, Panton-Valentine leukocidin, Pneumonia, adult, adolescent
1.
Dufour P, Gillet Y, Bes M, Lina G, Vandenesch F, Floret D, Etienne J, Richet H: Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002;35:819–824.
2.
Francis JS, Doherty MC, Lopatin U, Johnston CP, Sinha G, Ross T, Cai M, Hansel NN, Perl T, Ticehurst JR, Carroll K, Thomas DL, Nuermberger E, Bartlett JG: Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005;40:100–107.
3.
Holmes A, Ganner M, McGuane S, Pitt TL, Cookson BD, Kearns AM: Staphylococcus aureus isolates carrying Panton-Valentine leucocidin genes in England and Wales: frequency, characterization, and association with clinical disease. J Clin Microbiol 2005;43:2384–2390.
4.
Kelesidis T, Osman S, Trayner E, Worthington M, Celli B: Tracheobronchitis caused by methicillin-resistant Staphylococcus aureus as a cause of chronic wheezing in a non-ventilated adult patient with tracheobronchomalacia. Respiration 2010;80:148–156.
5.
Wenzel RP, Bearman G, Edmond MB: Community-acquired methicillin-resistant Staphylococcus aureus (MRSA): new issues for infection control. Int J Antimicrob Agents 2007;30:210–212.
6.
Perbet S, Soummer A, Vinsonneau C, Vandebrouck A, Rackelboom T, Etienne J, Cariou A, Chiche JD, Mira JP, Charpentier J: Multifocal community-acquired necrotizing fasciitis caused by a Panton-Valentine leukocidin-producing methicillin-sensitive Staphylococcus aureus. Infection 2010;38:223–225.
7.
Boussaud V, Parrot A, Mayaud C, Wislez M, Antoine M, Picard C, Delisle F, Etienne J, Cadranel J: Life-threatening hemoptysis in adults with community-acquired pneumonia due to Panton-Valentine leukocidin-secreting Staphylococcus aureus. Intensive Care Med 2003;29:1840–1843.
8.
Huang J, Zhang TT, Wu BQ, Zhu JX, Liu H, Zhou YQ: Prokaryotic expression of Staphylococcus aureus Panton-Valentine leukocidin and its cytolytic activities to human polymorphonuclear neutrophils. Chin J Pathophysiol 2008;24:1822–1829.
9.
Wu BQ, Zhang WX, Huang J, Liu H, Zhang TT: Effect of recombinant Panton-Valentine leukocidin in vitro on apoptosis and cytokine production of human alveolar macrophages. Can J Microbiol 2010;56:229–235.
10.
Labandeira-Rey M, Couzon F, Boisset S, Brown EL, Bes M, Benito Y, Barbu EM, Vazquez V, Höök M, Etienne J, Vandenesch F, Bowden MG: Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 2007;315:1130–1133.
11.
Konig B, Prevost G, Piemon Y, Konig W: Effects of Staphylococcus aureus leukocidins on inflammatory mediator release from human granulocytes. J Infect Dis 1995;171:607–613.
12.
Micek ST, Dunne M, Kollef MH: Pleuropulmonary complications of Panton-Valentine Leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005;128:2732–2738.
13.
Kefala-Agoropoulou K, Protonotariou E, Vitti D, Sarafidou S, Anastasiou A, Kollios K, Roilides E: Life-threatening infection due to community-acquired methicillin-resistant Staphylococcus aureus: case report and review. Eur J Pediatr 2010;169:47–53.
14.
Gillet Y, Vanhems P, Lina G, Bes M, Vandenesch F, Floret D, Etienne J: Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 2007;45:315–321.
15.
Vardakas KZ, Matthaiou DK, Falagas ME: Incidence, characteristics and outcomes of patients with severe CA-MRSA pneumonia. Eur Respir J 2009;34:1148–1158.
16.
Hageman JC, Uyeki TM, Francis JS, Jernigan DB, Wheeler JG, Bridges CB, Barenkamp SJ, Sievert DM, Srinivasan A, Doherty MC, McDougal LK, Killgore GE, Lopatin UA, Coffman R, MacDonald JK, McAllister SK, Fosheim GE, Patel JB, McDonald LC: Severe community-acquired pneumonia due to Staphylococcus aureus, 2003–04 influenza season. Emerg Infect Dis 2006;12:894–899.
17.
Kallen AJ, Brunkard J, Moore Z, Budge P, Arnold KE, Fosheim G, Finelli L, Beekmann SE, Polgreen PM, Gorwitz R, Hageman J: Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. Ann Emerg Med 2009;53:358–365.
18.
Vardakas KZ, Matthaiou DK, Falagas ME: Comparison of community-acquired pneumonia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus producing the Panton-Valentine leukocidin. Int J Tuberc Lung Dis 2009;13:1476–1485.
19.
Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, Vandenesch F, Piémont Y, Brousse N, Floret D, Etienne J: Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002;359:753–759.
20.
Lina G, Piémont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, Vandenesch F, Etienne J: Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999;29:1128–1132.
21.
Hidron AI, Low CE, Honig EG, Blumberg HM: Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia. Lancet Infect Dis 2009;9:384–392.
22.
Ruiz M, Ewig S, Marcos MA, Martinez JA, Arancibia F, Mensa J, Torres A: Etiology of community acquired pneumonia: impact of age, morbidity and severity. Am J Respir Crit Care Med 1999;160:397–405.
23.
Munckhof WJ, Nimmo GR, Carney J, Schooneveldt JM, Huygens F, Inman-Bamber J, Tong E, Morton A, Giffard P: Methicillin-susceptible, non-multiresistant methicillin-resistant and multiresistant methicillin-resistant Staphylococcus aureus infections: a clinical, epidemiological and microbiological comparative study. Eur J Clin Microbiol Infect Dis 2008;27:355–364.
24.
Shallcross LJ, Williams K, Hopkins S, Aldridge RW, Johnson AM, Hayward AC: Panton-Valentine leukocidin associated staphylococcal disease: a cross sectional study at a London hospital, England. Clin Microbiol Infect DOI: 10.1111/j.1469–0691.2009.03153.x
25.
Agwu A, Brady KM, Ross T, Carroll KC, Halsey NA: Cholera-like diarrhea and shock associated with community-acquired methicillin-resistant Staphylococcus aureus (USA400 clone) pneumonia. Pediatr Infect Dis J 2007;26:271–273.
26.
Vayalumkal JV, Whittingham H, Vanderkooi O, Stewart TE, Low DE, Mulvey M, McGeer A: Necrotizing pneumonia and septic shock: suspecting CA-MRSA in patients present- ing to Canadian emergency departments. CJEMed 2007;9:300–303.
27.
Enayet I, Nazeri A, Johnson LB, Riederer K, Pawlak J, Saravolatz LD: Community-associated methicillin-resistant Staphylococcus aureus causing chronic pneumonia. Clin Infect Dis 2006;42:e57–e60.
28.
Frazee BW, Salz TO, Lambert L, Perdreau-Remington F: Fatal community-associated methicillin-resistant Staphylococcus aureus pneumonia in an immunocompetent young adult. Ann Emerg Med 2005;46:401–404.
29.
Martino JL, McMillian WD, Polish LB, Dixon AE: Community-acquired methicillin-resistant Staphylococcus aureus pneumonia. Respir Med 2008;102;932–934.
30.
Centers for Disease Control and Prevention (CDC): Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza – Louisiana and Georgia, December 2006–January 2007. MMWR Morb Mortal Wkly Rep 2007;56:325–329.
31.
Gonzalez BE, Martinez-Aguilar G, Hulten KG, Hammerman WA, Coss Bu J, Avalos Mishaan A, Mason EO Jr, Kaplan SL: Severe Staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics 2005;115:642–648.
32.
Hasan SI, Hale EB: Community-acquired methicillin-resistant Staphylococcus aureus necrotizing pneumonia: a report of three cases. Hosp Physician 2008;44:37–41.
33.
Adam H, McGeer A, Simor A: Fatal case of post-influenza, community-associated MRSA pneumonia in an Ontario teenager with subsequent familial transmission. Can Commun Dis Rep 2007;33:45–48.
34.
Dickson RP, Martinez SM, Ortiz JR: A case of rapidly progressive necrotizing pneumonia caused by community-acquired methicillin-resistant Staphylococcus aureus. Respir Care 2008;53:1223–1226.
35.
Ebert MD, Sheth S, Fishman EK: Necrotizing pneumonia caused by community-acquired methicillin-resistant Staphylococcus aureus: an increasing cause of ‘mayhem in the lung’. Emerg Radiol 2009;16:159–162.
36.
Kravitz GR, Dries DJ, Peterson ML, Schlievert PM: Purpura fulminans due to Staphylococcus aureus. Clin Infect Dis 2005;40:941–947.
37.
Jones TF, Creech CB, Erwin P, Baird SG, Woron AM, Schaffner W: Family outbreaks of invasive community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2006;42:e76–e78.
38.
Rotas M, McCalla S, Liu C, Minkoff H: Methicillin-resistant Staphylococcus aureus necrotizing pneumonia arising from an infected episiotomy site. Obstet Gynecol 2007;109:533–536.
39.
Dicpinigaitis PV, Levy DE, Gnass RD, Bernstein RG: Pneumonia due to Staphylococcus aureus in a patient with AIDS: review of incidence and report of an atypical roentgenographic presentation. South Med J 1995;88:586–590.
40.
Castaldo ET, Yang EY: Severe sepsis attributable to community-associated methicillin-resistant Staphylococcus aureus: an emerging fatal problem. Am Surg 2007;73:684–687.
41.
Roberts JC, Gulino SP, Peak KK, Luna VA, Sanderson R: Fatal necrotizing pneumonia due to a Panton-Valentine leukocidin positive community-associated methicillin-sensitive Staphylococcus aureus and influenza co-infection: a case report. Ann Clin Microbiol Antimicrob 2008;7:5.
42.
Honarpour N, Mao JT: A case of fatal community-acquired necrotizing pneumonia caused by Panton-Valentine leukocidin positive methicillin-sensitive Staphylococcus aureus. Curr Respir Med Rev 2007;3:49–51.
43.
van der Flier M, van Dijk NB, Fluit AC, Fleer A, Wolfs TF, van Gestel JP: Fatal pneumonia in an adolescent due to community-acquired methicillin-resistant Staphylococcus aureus positive for Panton-Valentine leukocidin (in Dutch). Ned Tijdschr Geneeskd 2003;147:1076–1079.
44.
Valentini P, Parisi G, Monaco M, Crea F, Spanu T, Ranno O, Tronci M, Pantosti A: An uncommon presentation for a severe invasive infection due to methicillin-resistant Staphylococcus aureus clone USA300 in Italy: a case report. Ann Clin Microbiol Antimicrob 2008;7:11.
45.
Jung N, Lehmann C, Hellmann M, Seifert H, Valter MM, Hallek M, Fätkenheuer G, Kochanek M: Necrotizing pneumonia caused by Panton-Valentine leucocidin-producing Staphylococcus aureus originating from a Bartholin’s abscess. Infect Dis Obstet Gynecol 2008;2008:491401.
46.
Garnier F, Tristan A, François B, Etienne J, Delage-Corre M, Martin C, Liassine N, Wannet W, Denis F, Ploy MC: Pneumonia and new methicillin-resistant Staphylococcus aureus clone. Emerg Infect Dis 2006;12:498–500.
47.
Söderquist B, Berglund C, Strålin K: Community-acquired pneumonia and bacteremia caused by an unusual methicillin-resistant Staphylococcus aureus (MRSA) strain with sequence type 36, staphylococcal cassette chromosome mec type IV and Panton-Valentine leukocidin genes. Eur J Clin Microbiol Infect Dis 2006;25:604–606.
48.
Klein JL, Petrovic Z, Treacher D, Edgeworth J: Severe community-acquired pneumonia caused by Panton-Valentine leukocidin-positive Staphylococcus aureus: first reported case in the United Kingdom. Intensive Care Med 2003;29:1399.
49.
Gerogianni I, Mpatavanis G, Gourgoulianis K, Maniatis A, Spiliopoulou I, Petinaki E: Combination of staphylococcal chromosome cassette SCCmec type V and Panton-Valentine leukocidin genes in a methicillin-resistant Staphylococcus aureus that caused necrotizing pneumonia in Greece. Diagn Microbiol Infect Dis 2006;56:213–216.
50.
Alonso-Tarrés C, Villegas ML, de Gispert FJ, Cortés-Lletget MC, Rovira Plarromaní A, Etienne J: Favorable outcome of pneumonia due to Panton-Valentine leukocidin-producing Staphylococcus aureus associated with hematogenous origin and absence of flu-like illness. Eur J Clin Microbiol Infect Dis 2005;24:756–759.
51.
Monaco M, Antonucci R, Palange P, Venditti M, Pantosti A: Methicillin resistant Staphylococcus aureus necrotizing pneumonia. Emerg Infect Dis 2005;11:1647–1648.
52.
Magira EE, Zervakis D, Routsi C, Kontogiorgi M, Roussos C, Nanas S, Mentzelopoulos S: Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: a lethal cause of pneumonia in an adult immunocompetent patient. Scand J Infect Dis 2007;39:466–469.
53.
Balis E, Diacaki C, Tselioti P, Perimeni D, Vourli S, Vatopoulos A, Giamarellou HB, Prekates A: Community-acquired pneumonia and bacteremia due to methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin gene in Greece: two case reports and literature review. J Chemother 2007;19:703–708.
54.
Obed A, Schnitzbauer AA, Bein T, Lehn N, Linde HJ, Schlitt HJ: Fatal pneumonia caused by Panton-Valentine leucocidine-positive methicillin-resistant Staphylococcus aureus (PVL-MRSA) transmitted from a healthy donor in living-donor liver transplantation. Transplantation 2006;81:121–124.
55.
Tronci M, Parisi G, Pantosti A, Monaco M, Valentini P: A CA-MRSA strain with decreased vancomycin susceptibility as a cause of serious invasive infection in an immunocompetent adolescent. Clin Microbiol Infect 2007;13(suppl 1):S449.
56.
Hampson FG, Hancock SW, Primhak RA: Disseminated sepsis due to a Panton-Valentine leukocidin producing strain of community acquired methicillin resistant Staphylococcus aureus and use of intravenous immunoglobulin therapy. Arch Dis Child 2006;91:201.
57.
Michalopoulos A, Falagas ME: Multi-systemic methicillin resistant Staphylococcus aureus (MRSA) community-acquired infection. Med Sci Monit 2006;12:CS39–CS43.
58.
Miklasevics E, Haeggman S, Balode A, Sanchez B, Martinsons A, Olsson-Liljequist B, Dumpis U: Report on the first PVL-positive community acquired MRSA strain in Latvia. Euro Surveill 2004;9:29–30.
59.
Baldwin LN, Lowe AD: Panton-Valentine leukocidin associated with community acquired methicillin resistant Staphylococcus aureus: a case report and review of interim guidelines. Anaesthesia 2008;63:764–766.
60.
Quadri AM, Hock YL: Pulmonary pathology of Panton-Valentine leukocidin gene carrying methicillin-resistant Staphylococcus aureus pneumonia. Histopathology 2007;51:712–713.
61.
Torell E, Molin D, Tano E, Ehrenborg C, Ryden C: Community-acquired pneumonia and bacteraemia in a healthy young woman caused by methicillin-resistant Staphylococcus aureus (MRSA) carrying the genes encoding Panton-Valentine leukocidin (PVL). Scand J Infect Dis 2005;37:902–904.
62.
Turtle L, Wey E, James E: Severe pneumonia caused by ciprofloxacin resistant Panton-Valentine leukocidin producing community acquired methicillin resistant Staphylococcus aureus. J Infect 2009;58:86–89.
63.
Stefani S, Bongiorno D, Cafiso V, Campanile F, Crapis M, Cristini F, Sartor A, Scarparo C, Spina D, Viale P: Pathotype and susceptibility profile of a community-acquired methicillin-resistant Staphylococcus aureus strain responsible for a case of severe pneumonia. Diagn Microbiol Infect Dis 2009;63:100–104.
64.
Kuhn C, Markau S, Osten B: Abscettic pneumonia in a renal transplantation female patient (in German). Internist (Berl) 2005;46:789–794.
65.
Beilouny B, Ciupea A, Eloy C, Simon G: Fatal community-acquired pneumonia due to Staphylococcus aureus carrying Panton-Valentine leukocidin genes after a stay in Africa. Intensive Care Med 2008;34:388–389.
66.
Schefold JC, Esposito F, Storm C, Heuck D, Krüger A, Jörres A, Witte W, Hasper D: Therapy-refractory Panton-Valentine leukocidin-positive community-acquired methicillin-sensitive Staphylococcus aureus sepsis with progressive metastatic soft tissue infection: a case report. J Med Case Reports 2007;1:165.
67.
Laifer G, Frei R, Adler H, Fluckiger U: Necrotising pneumonia complicating a nasal furuncle. Lancet 2006;367:1628.
68.
Libert N, Borne M, Janvier F, Batjom E, Cirodde A, Nizou JY, Brinquin L: Successful treatment of life-threatening Panton-Valentine leucocidin positive Staphylococcus aureus pneumonia with antibiotics and immunoglobulins targeting the toxin production (in French). Rev Med Interne 2009;30:907–910.
69.
Mushtaq F, Hildrew S, Okugbeni G, Ellis RW, Deshpande S: Necrotizing haemorrhagic pneumonia proves fatal in an immunocompetent child due to Panton-Valentine leucocidin, toxic shock syndrome toxins 1 and 2 and enterotoxin C-producing Staphylococcus aureus. Acta Paediatr 2008;97:985–987.
70.
Ditzen A, Ehricht R, Monecke S: Disseminated cutaneous and pulmonary abscesses in an injecting drug user caused by a Panton-Valentine leucocidin-positive, methicillin-susceptible Staphylococcus aureus strain. Eur J Clin Microbiol Infect Dis 2008;27:1013–1015.
71.
Hyvernat H, Pulcini C, Carles D, Roques A, Lucas P, Hofman V, Hofman P, Bernardin G: Fatal Staphylococcus aureus haemorrhagic pneumonia producing Panton-Valentine leucocidin. Scand J Infect Dis 2007;39:183–185.
72.
van Nieuwkoop C, Bernards AT, Compier EA, Kraemer CV, Visser LG: Community-acquired Staphylococcus aureus pneumonia following influenza and the choice of empirical antibiotic treatment (in Dutch). Ned Tijdschr Geneeskd 2008;152:822–826.
73.
Tordecillas Echenique Y, Salamanca Bautista MP, Arias Jiménez JL, Guisado Espartero E, Ortega Calvo M, Pérez Cano R: Haematogeous sternal osteomyelitis and commu- nity pneumonia in a methicillin-susceptible Staphilococcus aureus sepsis (in Spanish). An Med Interna 2005;22:191–193.
74.
Salliot C, Zeller V, Puechal X, Manceron V, Sire S, Varache N, Etienne J, Desplaces N, Ziza JM: Panton-Valentine leukocidin-producing Staphylococcus aureus infections: report of 4 French cases. Scand J Infect Dis 2006;38:192–195.
75.
Lee YP, Hoi WH, Wong RCC: A case of myopericarditis in a patient with methicillin-resistant Staphylococcus aureus commu- nity-acquired pneumonia. Ann Acad Med Singapore 2008;37:243–244.
76.
Tomita Y, Kawano O, Ichiyasu H, Fukushima T, Fukuda K, Sugimoto M, Kohrogi H: Two cases of severe necrotizing pneumonia caused by community-acquired methicillin-resistant Staphylococcus aureus (in Japanese). Nihon Kokyuki Gakkai Zasshi 2008;46:395–403.
77.
Chua AP, Lee KH: Fatal bacteraemic pneumonia due to community-acquired methicillin-resistant Staphylococcus aureus. Singapore Med J 2006;47:546–548.
78.
Miyashita T, Shimamoto Y, Nishiya H: Destructive pulmonary embolism in a patient with community-acquired staphylococcal bacteremia. J Infect Chemother 2002;8:99–102.
79.
Hsu LY, Tristan A, Koh TH, Bes M, Etienne J, Kurup A, Tan TT, Tan BH: Community associated methicillin-resistant Staphylococcus aureus, Singapore. Emerg Infect Dis 2005;11:341–342.
80.
Al-Tawfiq JA, Aldaabil RA: Community-acquired MRSA bacteremic necrotizing pneumonia in a patient with scrotal ulceration. J Infect 2005;51:e241–243.
81.
Hsu LY, Koh TH, Anantham D, Kurup A, Chan KP, Tan BH: Panton-Valentine Leukocidin-positive Staphylococcus aureus, Singapore. Emerg Infect Dis 2004;10,1509–1510.
82.
Chetchotisakd P, Anunnatsiri S, Puapermpoonsiri S, Prariyachatgul C, Chumpol J: A rapidly fatal case of Panton-Valentine leukocidin positive SA necrotizing pneumonia in an HIV-infected patient. Southeast Asian J Trop Med Public Health 2007;38:690–694.
83.
Tong SY, Anstey NM, Lum GD, Lilliebridge RA, Stephens DP, Currie BJ: Fatal community-associated methicillin-resistant Staphylococcus aureus pneumonia after influenza. Med J Aust 2008;188:61.
84.
Risson DC, O’Connor ED, Guard RW, Schooneveldt JM, Nimmo GR: A fatal case of necrotising pneumonia due to community associated methicillin-resistant Staphylococcus aureus. Med J Aust 2007;186:479–480.
85.
Peleg AY, Munckhof WJ: Fatal necrotising pneumonia due to community-acquired methicillin-resistant Staphylococcus aureus (MRSA). Med J Aust 2004;181:228–229.
86.
Nimmo GR, Playford EG: Community-acquired MRSA bacteraemia: four additional cases including one associated with severe pneumonia. Med J Aust 2003;178:245.
87.
Peleg AY, Munckhof WJ, Kleinschmidt SL, Stephens AJ, Huygens F: Life-threatening community-acquired methicillin-resistant Staphylococcus aureus infection in Australia. Eur J Clin Microbiol Infect Dis 2005;24:384–387.
88.
Swaminathan A, Massasso D, Gotis-Graham I, Gosbell I: Fulminant methicillin-sensitive Staphylococcus aureus infection in a healthy adolescent, highlighting ‘Panton-Valentine leucocidin syndrome’. Intern Med J 2006;36:744–747.
89.
Crum-Cianflone NF, Burgi AA, Hale BR: Increasing rates of community-acquired Staphylococcus aureus infections among HIV-infected persons. Int J STD AIDS 2007;18:521–526.
90.
Utine GE, Pinar A, Ozçelik U, Sener B, Yalçin E, Doğru D, Menemenlioğlu D, Gür D, Kiper N, Göçmen A: Pleural fluid PCR method for detection of Staphylococcus aureus, Streptococcus pneumoniae and Haemophilus influenzae in pediatric parapneumonic effusions. Respiration 2008;75:437–442.
91.
Pantosti A, Sanchini A, Monaco M: Mechanisms of antibiotic resistance in Staphylococcus aureus. Future Microbiol 2007;2:323–334.
92.
Cecere LM, Rubenfeld GD, Park DR, Root RK, Goss CH: Long-term survival after hospitalization for community-acquired and healthcare-associated pneumonia. Respiration 2010;79:128–136.
93.
Snijders D, van der Eerden M, de Graaff C, Boersma W: The influence of COPD on mortality and severity scoring in community-acquired pneumonia. Respiration 2010;79:46–53.
94.
Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243–250.
95.
Wargo KA, Eiland EH: Appropriate antimicrobial therapy for community-acquired methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005;40:1376–1378.
96.
Genestier AL, Michallet MC, Prevost G, Bellot G, Chalabreysse L, Peyrol S, Thivolet F, Etienne J, Lina G, Vallette FM, Vandenesch F, Genestier L: Staphylococcus aureus Panton-Valentine leukocidin directly targets mitochondria and induces Bax-independent apoptosis of human neutrophils. J Clin Invest 2005;115:3117–3127.
97.
de Bentzmann S, Tristan A, Etienne J, Brousse N, Vandenesch F, Lina G: Staphylococcus aureus isolates associated with necrotizing pneumonia bind to basement membrane type I and IV collagens and laminin. J Infect Dis 2004;190:1506–1515.
98.
Hasty MB, Klasner A, Kness S, Denmark TK, Ellis D, Herman MI, Brown L: Cutaneous community-associated methicillin-resistant Staphylococcus aureus among all skin and soft-tissue infections in two geographically distant pediatric emergency departments. Acad Emerg Med 2007;14:35–40.
99.
Gorwitz R, Fridkin SK, Workowski KA: More challenges in the prevention and management of community-associated, methicillin-resistant Staphylococcus aureus skin disease. Ann Intern Med 2008;148:310–312.
100.
Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27–S72.
101.
Mohr JF, Murray BE: Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007;44:1536–1542.
102.
Deresinski S: Counterpoint: vancomycin and Staphylococcus aureus. An antibiotic enters obsolescence. Clin Infect Dis 2007;44:1543–1548.
103.
Micek ST: Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2007;45:S184-S190.
104.
Wunderink RG, Rello J, Cammarate SK, Croos-Dabrera RV, Kollef MH: Linezolid vs. vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789–1797.
105.
Brugraro P, Eseme F, Morelli E, Fiscon M, Rosini G, Belussi F, Ebo F, Petrucci A, Tenderini P, Raise E: Antibiotic regimen including linezolid for treating prosthetic valve endocarditis with cerebral embolism due to methicillin-susceptible Staphylococcus aureus after failure with oxacillin and teicoplanin. Infez Med 2009;17:240–243.
106.
Bernardo K, Pakulat N, Fleer S, Schnaith A, Utermöhlen O, Krut O, Müller S, Krönke M: Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 2004;48:546–555.
107.
Honeybourne D, Tobin C, Jevons G, Andrews J, Wise R: Intrapulmonary penetration of linezolid. J Antimicrob Chemother 2003;51:1431–1444.
108.
Stevens DL, Dotter B, Madaras-Kelly K: A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther 2004;2:51–59.
109.
Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE: Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007;195:202–211.
110.
Siberry GK, Tekle T, Carroll K, Dick J: Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003;37:1257–1260.
111.
Wang JL, Chen SY, Wang GT, Wu GH, Chiang WC, Hsueh PR, Chen YC, Chang SC: Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus. Clin Infect Dis 2008;46:799–806.
112.
Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS: Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003;37:1050–1058.
113.
Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR, Heffernan H, Liassine N, Bes M, Greenland T, Reverdy ME, Etienne J: Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003;9:978–984.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.